Literature DB >> 9989788

Bullous pemphigoid sera that contain antibodies to BPAg2 also contain antibodies to LABD97 that recognize epitopes distal to the NC16A domain.

C A Egan1, T B Taylor, L J Meyer, M J Petersen, J J Zone.   

Abstract

IgG antibodies from the sera of some patients with bullous pemphigoid (BP) react with a 180 kDa protein termed BPAg2. Antibodies in BP are directed to an extracellular noncollagenous domain of this protein termed NC16A. Our group has recently shown that a portion of the extracellular domain of BPAg2 is identical to LABD97 on the basis of amino acid sequencing. We evaluated sera from 33 patients with BP with circulating IgG antibodies on indirect immunofluorescence, which stained the epidermal side of split skin with titers ranging from 1:40 to 1:640. Immunoblotting was performed against (i) two preparations of proteins from epidermal extract, one containing BPAg2 and one containing LABD97, and (ii) the recombinant NC16A domain of the BPAg2 protein. Twelve sera reacted with the BPAg2 protein. Ten of these also reacted strongly with the NC16A domain. Nine of the 12 sera also reacted with the LABD97 antigen. Bound antibodies were eluted from the 97 kDa band and reapplied to split skin where they bound to the epidermal side. The eluted antibodies also reacted to the BPAg2 protein from the epidermal extract, but did not react with the NC16A domain on immunoblot. We conclude that these nine sera react with an epitope present within BPAg2 and LABD97 but not within the NC16A domain. This epitope is therefore distal to the previously described epitopes in BP. In BP, epitope spreading may occur and antibodies may be produced that recognize the distal portion of the BPAg2 molecule identical to LABD97 but that do not involve the NC16A domain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989788     DOI: 10.1046/j.1523-1747.1999.00490.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases.

Authors:  H Schumann; J Baetge; K Tasanen; F Wojnarowska; H Schäcke; D Zillikens; L Bruckner-Tuderman
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway.

Authors:  Sho Hiroyasu; Toshiyuki Ozawa; Hiromi Kobayashi; Masamitsu Ishii; Yumi Aoyama; Yasuo Kitajima; Takashi Hashimoto; Jonathan C R Jones; Daisuke Tsuruta
Journal:  Am J Pathol       Date:  2013-01-19       Impact factor: 4.307

3.  The flavonoid luteolin inhibits Fcγ-dependent respiratory burst in granulocytes, but not skin blistering in a new model of pemphigoid in adult mice.

Authors:  Eva Oswald; Alina Sesarman; Claus-Werner Franzke; Ute Wölfle; Leena Bruckner-Tuderman; Thilo Jakob; Stefan F Martin; Cassian Sitaru
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

Review 4.  Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid.

Authors:  Connor Cole; Luca Borradori; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2022-06-28

5.  IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.

Authors:  P C Freire; C H Muñoz; G Stingl
Journal:  Br J Dermatol       Date:  2017-11-28       Impact factor: 9.302

6.  A PTEN-COL17A1 fusion gene and its novel regulatory role in Collagen XVII expression and GBM malignance.

Authors:  Xiaoyan Yan; Chuanbao Zhang; Tingyu Liang; Fan Yang; Haoyuan Wang; Fan Wu; Wen Wang; Zheng Wang; Wen Cheng; Jiangnan Xu; Tao Jiang; Jing Chen; Yaozhong Ding
Journal:  Oncotarget       Date:  2017-08-24

7.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.